Key Segmentation:
By Drug
-
Tenofovir Disoproxil Fumarate (TDF)
-
Tenofovir Alafenamide (TAF)
-
Emtricitabine (FTC)
-
Cabotegravir Long-Acting
-
Lenacapavir
-
Other Drugs
By Dosage Form
-
Oral Pill
-
Long-Acting Injectable
-
Sub-Dermal Implant
-
Topical Microbicide (Gel/Film)
-
Vaginal Ring
By Prophylaxis Type
-
Pre-Exposure Prophylaxis (PrEP)
-
Post-Exposure Prophylaxis (PEP)
By Distribution Channel
-
Hospital Pharmacies
-
Retail Pharmacies
-
Online Pharmacies & Tele-PrEP Platforms
-
Community-Based Clinics & NGOs
Regional Coverage:
North America
-
US
-
Canada
Europe
-
Germany
-
UK
-
France
-
Italy
-
Spain
-
Russia
-
Poland
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market player
Frequently Asked Questions
Key players include Gilead Sciences, Inc., ViiV Healthcare (GSK plc), Merck & Co., Inc., Cipla Ltd., and Viatris Inc., among others.
Key opportunities include voluntary generic licensing of long-acting agents, expansion of tele-PrEP and digital delivery models, and donor-funded PrEP scale-up across sub-Saharan Africa and Asia-Pacific.
The primary growth factor is the continued burden of new HIV infections, combined with the rapid shift toward long-acting injectable prophylaxis that improves adherence.
By drug, the Tenofovir Alafenamide (TAF) segment dominates the Prophylactic HIV Drugs Market with approximately 53.62% share in 2025.
North America dominates the Prophylactic HIV Drugs Market with approximately 41.48% share in 2025.
